A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.

NCT ID: NCT00905489

Last Updated: 2016-01-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 85 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-06-30
• Study Completion Date: 2012-09-30

Brief Summary

The primary objective is to establish the pharmacokinetic (PK) profile at steady state of nevirapine XR in HIV infected children from >=3 to <18 years of age. This phase I trial is an open-label, multiple dose, non-randomized and cross-over study. Patients who have completed the last visit of the PK trial (visit 7) can enter into an Optional Extension Phase (OEP) until the Investigational New Drug (IND) is withdrawn; until nevirapine XR becomes approved and is available by prescription in a given country; or, the patient enrolls in a compassionate use program. During this OEP, nevirapine XR safety and efficacy information will be collected.

Conditions

HIV Infections

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Nevirapine IR / Nevirapine XR

In this pharmaco-kinetic (PK) cross-over design trial, all patients initially receive nevirapine immediate release and then all patients are switched to nevirapine extended release 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).

Group Type: EXPERIMENTAL

Nevirapine Immediate Release (IR)

Intervention Type: DRUG

200 mg Tablet or 50 mg / 5 ml oral suspension

Nevirapine Extended Release (XR)

Intervention Type: DRUG

200 mg, 300 mg or 400 mg Tablet formulation

Interventions

Nevirapine Immediate Release (IR)

200 mg Tablet or 50 mg / 5 ml oral suspension

Intervention Type: DRUG

Nevirapine Extended Release (XR)

200 mg, 300 mg or 400 mg Tablet formulation

Intervention Type: DRUG

Other Intervention Names

Nevirapine IR; Nevirapine XR

Eligibility Criteria

Inclusion Criteria

1. Signed and dated written informed consent of a parent or legal guardian prior to admission. Active assent must be given by the patient if the child and/or adolescent is capable of understanding the provided study information.

2. HIV-1 infected males or females >= 3 and < 18 years old.

3. BSA >= 0.58 m2 for patients using BSA to calculate nevirapine IR dose; or BW >= 12.5 kg for patients using BW to calculate nevirapine IR dose at screening visit.

4. Treated with a nevirapine IR based regimen for at least 18 weeks prior to screening visit (Visit 1); no modifications in the ARV background therapy within the last 2 weeks prior to screening.

5. An HIV VL of <50 copies/mL while receiving nevirapine IR at the last measure of VL documented in the medical record obtained within a period of 5 months prior to screening visit.

6. An HIV VL of <50 copies/mL at screening visit.

7. A stable or not decreasing CD4+ cell count according to the investigator's opinion.

8. Acceptable screening laboratory values that indicate adequate baseline organ function according to the opinion of investigator.

9. ALT and AST <= 2.5 X ULN (DAIDS Grade 1).

10. Serum creatinine levels <= 1.3 X ULN (DAIDS Grade 1).

11. Patients able to swallow tablets.

Exclusion Criteria

1. Any AIDS-related or AIDS defining illness that is unresolved or not stable on treatment at least 8 weeks prior to screening visit.

2. Diseases other than HIV infection or conditions that, in the investigator's opinion, would interfere with the study.

3. Patients who have been diagnosed with malignant disease and who are receiving systemic chemotherapy or are anticipated to receive any therapy during their participation in this trial.

4. Use of investigational medications or vaccines within 28 days prior to Visit 1 or during the trial.

5. Use of immunomodulatory drugs within 28 days before Visit 1 or during the trial (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2).

6. Concomitant protease inhibitor (PI) treatment.

7. Unwillingness to abstain from ingesting substances during the study which may alter plasma drug concentrations by interaction with the cytochrome P450 system (Appendix 10.2).

8. Female patients of childbearing potential who:

• have a positive serum pregnancy test at screening,
• are breast feeding,
• are planning on becoming pregnant,
• are not willing to use double-barrier methods

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

1100.1518.0001 Boehringer Ingelheim Investigational Site

Washington D.C., District of Columbia, United States

1100.1518.0002 Boehringer Ingelheim Investigational Site

Philadelphia, Pennsylvania, United States

1100.1518.2605 Boehringer Ingelheim Investigational Site

Francistown, , Botswana

1100.1518.2601 Boehringer Ingelheim Investigational Site

Gaborone, , Botswana

1100.1518.2603 Boehringer Ingelheim Investigational Site

Gaborone, , Botswana

1100.1518.4902 Boehringer Ingelheim Investigational Site

Berlin, , Germany

1100.1518.4901 Boehringer Ingelheim Investigational Site

Frankfurt am Main, , Germany

1100.1518.4903 Boehringer Ingelheim Investigational Site

München, , Germany

1100.1518.2702 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

1100.1518.2703 Boehringer Ingelheim Investigational Site

Parow Valley, , South Africa

Countries

United States; Botswana; Germany; South Africa

Other Identifiers

2008-005855-61

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1100.1518

Identifier Type: -

Identifier Source: org_study_id